Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT04975399
·
clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
26
Enrollment
INDUSTRY
Sponsor class
Stopped
Business objectives have changed
Conditions
Multiple Myeloma
Interventions
DRUG:
CC-92328
Sponsor
Celgene